Human Solid Tumors and Clinical Relevance of The Enhanced Permeation and Retention Effect: A ‘Golden Gate’ for Nanomedicine in Preclinical Studies?

References

• Siegel RL , MillerKD, FuchsHE, JemalA. Cancer statistics, 2022. Ca Cancer J. Clin.72(1), 7–33 (2022).
   PubMed Web of Science ®Google Scholar
• Maeda H , TsukigawaK, FangJ. A retrospective 30 years after discovery of the enhanced permeability and retention effect of solid tumors: next-generation chemotherapeutics and photodynamic therapy – problems, solutions, and prospects. Microcirculation.23(3), 173–182 (2016).
   PubMed Web of Science ®Google Scholar
• Nakamura H , FangJ, JunF, MaedaH. Development of next-generation macromolecular drugs based on the EPR effect: challenges and pitfalls. Expert Opin. Drug Deliv.12(1), 53–64 (2015).
   PubMed Web of Science ®Google Scholar
• Matsumura Y , MaedaH. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res.46(12 Pt 1), 6387–92 (1986).
   PubMed Web of Science ®Google Scholar
• Greish K . Enhanced permeability and retention of macromolecular drugs in solid tumors: a royal gate for targeted anticancer nanomedicines. J. Drug Target.15(7–8), 457–464 (2007).
   PubMed Web of Science ®Google Scholar
• Nichols JW , BaeYH. EPR: Evidence and fallacy. J. Control. Rel.190, 451–464 (2014).
   PubMed Web of Science ®Google Scholar
• Melincovici CS , BoşcaAB, ŞuşmanSet al. Vascular endothelial growth factor (VEGF) – key factor in normal and pathological angiogenesis. Rom. J. Morphol. Embryol.59(2), 455–67 (2018).
   PubMed Web of Science ®Google Scholar
• Goradel NH , NajafiM, SalehiEet al. Cyclooxygenase-2 in cancer: A review. J. Cell. Physiol.234(5), 5683–5699 (2019).
   PubMed Web of Science ®Google Scholar
• Somasundaram V , BasudharD, BharadwajGet al. Molecular mechanisms of nitric oxide in cancer progression, signal transduction, and metabolism. Antioxid. Redox. Sign.30(8), 1124–1143 (2019).
   PubMed Web of Science ®Google Scholar
• Hofseth LJ , HussainSP, WoganGN, HarrisCC. Nitric oxide in cancer and chemoprevention. Free Radical Bio. Med.34(8), 955–968 (2003).
   PubMed Web of Science ®Google Scholar
• Gabizon AA , de RosalesRTM, La-BeckNM. Translational considerations in nanomedicine: the oncology perspective. Adv. Drug Deliv. Rev.158, 140–157 (2020).
   PubMed Web of Science ®Google Scholar
• Saraswat A , PatkiM, FuYet al. Nanoformulation of proteolysis targeting chimera targeting ‘undruggable’ c-Myc for the treatment of pancreatic cancer. Nanomedicine (Lond.)15(18), 1761–1777 (2020).
   PubMed Web of Science ®Google Scholar
• Doddapaneni R , PatelK, OwaidIH, SinghM. Tumor neovasculature-targeted cationic PEGylated liposomes of gambogic acid for the treatment of triple-negative breast cancer. Drug Deliv.23(4), 1232–1241 (2016).
   PubMed Web of Science ®Google Scholar
• Chowdhury N , VhoraI, PatelKet al. Liposomes co-loaded with 6-phosphofructo-2-kinase/fructose-2, 6-biphosphatase 3 (PFKFB3) shRNA plasmid and docetaxel for the treatment of non-small-cell lung cancer. Pharm. Res.34(11), 2371–2384 (2017).
   PubMed Web of Science ®Google Scholar
• Fu Y , SaraswatA, WeiZet al. Development of dual ARV-825 and nintedanib-loaded PEGylated nano-liposomes for synergistic efficacy in vemurafnib-resistant melanoma. Pharmaceutics13(7), 1005 (2021).
   PubMed Web of Science ®Google Scholar
• Vemana HP , SaraswatA, BhutkarSet al. A novel gene therapy for neurodegenerative Lafora disease via EPM2A-loaded DLinDMA lipoplexes. Nanomedicine (Lond.)16(13), 1081–1095 (2021).
   PubMed Web of Science ®Google Scholar
• Saraswat AL , MaherTJ. Development and optimization of stealth liposomal system for enhanced in vitro cytotoxic effect of quercetin. J. Drug Deliv. Sci. Tec.55, 101477 (2020).
   Web of Science ®Google Scholar
• Fang J , SawaT, MaedaH. Factors and mechanism of ‘EPR’ effect and the enhanced antitumor effects of macromolecular drugs including SMANCS. Adv. Exp. Med. Biol.519, 29–49 (2003).
   PubMed Web of Science ®Google Scholar
• Barenholz Y . Doxil® – the first FDA-approved nano-drug: lessons learned. J. Control. Rel.160(2), 117–134 (2012).
   PubMed Web of Science ®Google Scholar
• Silverman JA , DeitcherSR. Marqibo® (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine. Cancer Chemother. Pharmacol.71(3), 555–564 (2013).
   PubMed Web of Science ®Google Scholar
• Zhang H . Onivyde for the therapy of multiple solid tumors. Oncotargets Ther.9, 3001–3007 (2016).
   PubMed Web of Science ®Google Scholar
• Patra JK , DasG, FracetoLFet al. Nano based drug delivery systems: recent developments and future prospects. J. Nanobiotechnol.16(1), 71 (2018).
   PubMed Web of Science ®Google Scholar
• Maeda H . The 35th anniversary of the discovery of EPR effect: a new wave of nanomedicines for tumor-targeted drug delivery – personal remarks and future prospects. J. Per. Med.11(3), 229 (2021).
   PubMed Web of Science ®Google Scholar
• Roma-Rodrigues C , MendesR, BaptistaPV, FernandesAR. Targeting tumor microenvironment for cancer therapy. Int. J. Mol. Sci.20(4), 840 (2019).
   PubMed Web of Science ®Google Scholar
• Golombek SK , MayJ-N, TheekBet al. Tumor targeting via EPR: strategies to enhance patient responses. Adv. Drug Deliv. Rev.130, 17–38 (2018).
   PubMed Web of Science ®Google Scholar
• Yu Y , CuiJ. Present and future of cancer immunotherapy: a tumor microenvironmental perspective. Oncol. Lett.16(4), 4105–4113 (2018).
   PubMed Web of Science ®Google Scholar
• Sugahara M , TanakaT, NangakuM. Hypoxia-inducible factor and oxygen biology in the kidney. Kidney 3601(9), 1021–1031 (2020).
   PubMedGoogle Scholar
• Iyer AK , KhaledG, FangJ, MaedaH. Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov. Today11(17–18), 812–818 (2006).
   PubMed Web of Science ®Google Scholar
• Narum SM , LeT, LeDPet al. Passive targeting in nanomedicine: fundamental concepts, body interactions, and clinical potential. In: Nanoparticles for Biomedical Applications.Elsevier, PA, USA, 37–53 (2020).
   Google Scholar
• de Lázaro I , MooneyDJ. A nanoparticle’s pathway into tumours. Nat. Mater.19(5), 486–487 (2020).
   PubMed Web of Science ®Google Scholar
• Din FU , AmanW, UllahIet al. Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors. Int. J. Nanomed.12, 7291–7309 (2017).
   PubMed Web of Science ®Google Scholar
• Bazak R , HouriM, AchySet al. Passive targeting of nanoparticles to cancer: a comprehensive review of the literature. Mol. Clin. Oncol.2(6), 904–908 (2014).
   PubMedGoogle Scholar
• Ferretti S , AllegriniPR, BecquetMM, McSheehyPMJ. Tumor interstitial fluid pressure as an early-response marker for anticancer therapeutics. Neoplasia11(9), 874–881 (2009).
   PubMed Web of Science ®Google Scholar
• Lu Y , HuD, YingW. A fast numerical method for oxygen supply in tissue with complex blood vessel network. PLOS ONE16(2), e0247641 (2021).
   PubMed Web of Science ®Google Scholar
• Vaupel P . The role of hypoxia-induced factors in tumor progression. Oncology9(S5), 10–17 (2004).
   Google Scholar
• Folkman J . Tumor angiogenesis. Adv. Cancer Res.43, 175–203 (1985).
   PubMed Web of Science ®Google Scholar
• Padera TP , MeijerEFJ, MunnLL. The lymphatic system in disease processes and cancer progression. Annu. Rev. Biomed. Eng.18(1), 1–34 (2015).
   Google Scholar
• Torchilin VP . Passive and active drug targeting: drug delivery to tumors as an example. Handb. Exp. Pharmacol. (197), 3–53 (2010).
   PubMedGoogle Scholar
• Danhier F . To exploit the tumor microenvironment: since the EPR effect fails in the clinic, what is the future of nanomedicine?J. Control. Rel.244(Pt A), 108–121 (2016).
   PubMedGoogle Scholar
• Ayloo S , GuC. Transcytosis at the blood–brain barrier. Curr. Opin. Neurobiol.57, 32–38 (2019).
   PubMed Web of Science ®Google Scholar
• Nel A , RuoslahtiE, MengH. New insights into ‘permeability’ as in the enhanced permeability and retention effect of cancer nanotherapeutics. ACS Nano11(10), 9567–9569 (2017).
   PubMed Web of Science ®Google Scholar
• Zhou Q , LiJ, XiangJet al. Transcytosis-enabled active extravasation of tumor nanomedicine. Adv. Drug. Deliv. Rev.189, 114480 (2022).
   PubMed Web of Science ®Google Scholar
• Pandit S , DuttaD, NieS. Active transcytosis and new opportunities for cancer nanomedicine. Nat. Mater.19(5), 478–480 (2020).
   PubMed Web of Science ®Google Scholar
• Liu X , JiangJ, MengH. Transcytosis – an effective targeting strategy that is complementary to ‘EPR effect’ for pancreatic cancer nano drug delivery. Theranostics9(26), 8018–8025 (2019).
   PubMed Web of Science ®Google Scholar
• Liu X , JiangJ, NelAE, MengH. Major effect of transcytosis on nano drug delivery to pancreatic cancer. Mol. Cell. Oncol.4(4), e1335273 (2017).
   PubMedGoogle Scholar
• Matsumura Y . Cancer stromal targeting therapy to overcome the pitfall of EPR effect. Adv. Drug Deliv. Rev.154, 142–150 (2020).
   PubMed Web of Science ®Google Scholar
• Yu W , LiuR, ZhouY, GaoH. Size-tunable strategies for a tumor targeted drug delivery system. ACS Central Sci.6(2), 100–116 (2020).
   PubMed Web of Science ®Google Scholar
• Yu W , ShevtsovM, ChenX, GaoH. Advances in aggregatable nanoparticles for tumor-targeted drug delivery. Chinese Chem. Lett.31(6), 1366–1374 (2020).
   Web of Science ®Google Scholar
• Liu R , YuM, YangXet al. Linear chimeric triblock molecules self-assembled micelles with controllably transformable property to enhance tumor retention for chemo-photodynamic therapy of breast cancer. Adv. Funct. Mater.29(23), 1808462 (2019).
   Web of Science ®Google Scholar
• Jia W , LiuR, WangYet al. Dual-responsive nanoparticles with transformable shape and reversible charge for amplified chemo-photodynamic therapy of breast cancer. Acta Pharm. Sinica B.12(8), 3354–3366 (2022).
   PubMed Web of Science ®Google Scholar
• van Vlerken LE , DuanZ, LittleSRet al. Biodistribution and pharmacokinetic analysis of paclitaxel and ceramide administered in multifunctional polymer-blend nanoparticles in a drug-resistant breast cancer model. Mol. Pharm.5, 516–526 (2008).
   PubMed Web of Science ®Google Scholar
• Izci M , MaksoudianC, ManshianBB, SoenenSJ. The use of alternative strategies for enhanced nanoparticle delivery to solid tumors. Chem. Rev.121(3), 1746–1803 (2021).
   PubMed Web of Science ®Google Scholar
• Wilhelm S , TavaresAJ, DaiQet al. Analysis of nanoparticle delivery to tumours. Nat. Rev. Mater.1(5), 16014 (2016).
   Web of Science ®Google Scholar
• McNeil SE . Evaluation of nanomedicines: stick to the basics. Nat. Rev. Mater.1(10), 16073 (2016).
   Web of Science ®Google Scholar
• Price LSL , SternST, DealAMet al. A reanalysis of nanoparticle tumor delivery using classical pharmacokinetic metrics. Sci. Adv.6(29), eaay9249 (2020).
   PubMed Web of Science ®Google Scholar
• Bhowmik S , BhowmickS, MaitiKet al. Two multicenter phase I randomized trials to compare the bioequivalence and safety of a generic doxorubicin hydrochloride liposome injection with Doxil® or Caelyx® in advanced ovarian cancer. Cancer Chemother. Pharmacol.82(3), 521–532 (2018).
   PubMed Web of Science ®Google Scholar
• Crain ML . Daunorubicin & Cytarabine liposome (Vyxeos™). Oncol. Times40(10), 30 (2018).
   Google Scholar
• Romeo C , JolyF, Ray-CoquardIet al. Non-pegylated liposomal doxorubicin (NPLD, Myocet®) + carboplatin in patients with platinum sensitive ovarian cancers: a ARCAGY-GINECO phase IB-II trial. Gynecol. Oncol.152(1), 68–75 (2018).
   PubMed Web of Science ®Google Scholar
• Kim D-W , KimS-Y, KimH-Ket al. Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer. Ann. Oncol.18(12), 2009–2014 (2007).
   PubMed Web of Science ®Google Scholar
• Bracken MB . Why animal studies are often poor predictors of human reactions to exposure. J. R. Soc. Med.102(3), 120–122 (2009).
   PubMed Web of Science ®Google Scholar
• Heldin C-H , RubinK, PietrasK, ÖstmanA. High interstitial fluid pressure – an obstacle in cancer therapy. Nat. Rev. Cancer.4(10), 806–813 (2004).
   PubMed Web of Science ®Google Scholar
• Huynh E , ZhengG. Cancer nanomedicine: addressing the dark side of the enhanced permeability and retention effect. Nanomedicine (Lond.)10(13), 1993–1995 (2015).
   PubMed Web of Science ®Google Scholar
• Guerin MV , FinisguerraV, den EyndeBJVet al. Preclinical murine tumor models: a structural and functional perspective. Elife.9, e50740 (2020).
   PubMed Web of Science ®Google Scholar
• Jung J . Human tumor xenograft models for preclinical assessment of anticancer drug development. Toxicol. Res.30(1), 1–5 (2014).
   PubMedGoogle Scholar
• Natfji AA , RavishankarD, OsbornHMI, GrecoF. Parameters affecting the enhanced permeability and retention effect: the need for patient selection. J. Pharm. Sci.106(11), 3179–3187 (2017).
   PubMed Web of Science ®Google Scholar
• Ozao-Choy J , MaG, KaoJet al. The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res.69(6), 2514–2522 (2009).
   PubMed Web of Science ®Google Scholar
• Carter CL , AllenC, HensonDE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer63(1), 181–187 (1989).
   PubMed Web of Science ®Google Scholar
• Danhier F , PréatV. Strategies to improve the EPR effect for the delivery of anti-cancer nanomedicines. Cancer Cell. Microenviron.2(3), e808, 1–7 (2015).
   Google Scholar
• Nichols JW , BaeYH. Odyssey of a cancer nanoparticle: From injection site to site of action. Nano Today7(6), 606–618 (2012).
   PubMed Web of Science ®Google Scholar
• Yuan F , LeunigM, HuangSKet al. Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res.54(13), 3352–3356 (1994).
   PubMed Web of Science ®Google Scholar
• Thomas OS , WeberW. Overcoming physiological barriers to nanoparticle delivery – are we there yet?Front. Bioeng. Biotechnol.7, 415 (2019).
   PubMed Web of Science ®Google Scholar
• de Jong M , MainaT. Of mice and humans: are they the same? – Implications in cancer translational research. J. Nucl. Med.51(4), 501–504 (2010).
   PubMed Web of Science ®Google Scholar
• Siolas D , HannonGJ. Patient-derived tumor xenografts: transforming clinical samples into mouse models. Cancer Res.73(17), 5315–5319 (2013).
   PubMed Web of Science ®Google Scholar
• Fu Y , RathodD, PatelK. Protein kinase C inhibitor anchored BRD4 PROTAC PEGylated nanoliposomes for the treatment of vemurafenib-resistant melanoma. Exp. Cell. Res.396(1), 112275 (2020).
   PubMed Web of Science ®Google Scholar
• Nakamura Y , MochidaA, ChoykePL, KobayashiH. Nanodrug delivery: is the enhanced permeability and retention effect sufficient for curing cancer?Bioconjugate Chem.27(10), 2225–2238 (2016).
   PubMed Web of Science ®Google Scholar
• Brooks DP , RuffoloRR. Pharmacological mechanism of angiotensin II receptor antagonists: implications for the treatment of elevated systolic blood pressure. J. Hypertens. Suppl. Official J. Int. Soc. Hypertens.17(2), S27–32 (1999).
   PubMedGoogle Scholar
• Chiaverina G , di BlasioL, MonicaVet al. Dynamic interplay between pericytes and endothelial cells during sprouting angiogenesis. Cells8(9), 1109 (2019).
   PubMed Web of Science ®Google Scholar
• Burton AC . Relation of structure to function of the tissues of the wall of blood vessels. Physiol. Rev.34(4), 619–642 (1954).
   PubMed Web of Science ®Google Scholar
• Greish K . Enhanced permeability and retention (EPR) effect for anticancer nanomedicine drug targeting. Methods Mol. Biol. Clifton N J.624, 25–37 (2010).
   PubMedGoogle Scholar
• Suzuki M , HoriK, AbeIet al. A new approach to cancer chemotherapy: selective enhancement of tumor blood flow with angiotensin II. J. Natl. Cancer Inst.67(3), 663–9 (1981).
   PubMedGoogle Scholar
• Li CJ , MiyamotoY, KojimaY, MaedaH. Augmentation of tumour delivery of macromolecular drugs with reduced bone marrow delivery by elevating blood pressure. Br. J. Cancer67(5), 975–980 (1993).
   PubMed Web of Science ®Google Scholar
• Subhan MA , YalamartySSK, FilipczakNet al. Recent advances in tumor targeting via ePR effect for cancer treatment. J. Pers. Med.11(6), 571 (2021).
   PubMed Web of Science ®Google Scholar
• Yasuda H , YamayaM, NakayamaKet al. Randomized phase II trial comparing nitroglycerin plus vinorelbine and cisplatin with vinorelbine and cisplatin alone in previously untreated stage IIIB/IV non-small-cell lung cancer. J. Clin. Oncol.24(4), 688–694 (2006).
   PubMed Web of Science ®Google Scholar
• Islam W , FangJ, ImamuraTet al. Augmentation of the enhanced permeability and retention effect with nitric oxide-generating agents improves the therapeutic effects of nanomedicines. Mol. Cancer Ther.17(12), 2643–2653 (2018).
   PubMed Web of Science ®Google Scholar
• Yoshikawa T , MoriY, FengHet al. Rapid and continuous accumulation of nitric oxide-releasing liposomes in tumors to augment the enhanced permeability and retention (EPR) effect. Int. J. Pharm.565, 481–487 (2019).
   PubMed Web of Science ®Google Scholar
• Divakaran S , LoscalzoJ. The role of nitroglycerin and other nitrogen oxides in cardiovascular therapeutics. J. Am. Coll. Cardiol.70(19), 2393–2410 (2017).
   PubMed Web of Science ®Google Scholar
• Ojha T , PathakV, ShiYet al. Pharmacological and physical vessel modulation strategies to improve EPR-mediated drug targeting to tumors. Adv. Drug Delive. Rev.119, 44–60 (2017).
   PubMed Web of Science ®Google Scholar
• Dimcevski G , KotopoulisS, BjånesTet al. A human clinical trial using ultrasound and microbubbles to enhance gemcitabine treatment of inoperable pancreatic cancer. J. Control. Rel.243, 172–181 (2016).
   PubMed Web of Science ®Google Scholar
• Theek B , BauesM, OjhaTet al. Sonoporation enhances liposome accumulation and penetration in tumors with low EPR. J. Control. Rel.231, 77–85 (2016).
   PubMed Web of Science ®Google Scholar
• Lee H , HanJ, ShinHet al. Combination of chemotherapy and photodynamic therapy for cancer treatment with sonoporation effects. J. Control. Rel.283, 190–199 (2018).
   PubMed Web of Science ®Google Scholar
• Deng CX . Targeted drug delivery across the blood–brain barrier using ultrasound technique. Ther. Deliv.1(6), 819–48 (2010).
   PubMedGoogle Scholar
• Treat LH , McDannoldN, ZhangYet al. Improved anti-tumor effect of liposomal doxorubicin after targeted blood–brain barrier disruption by MRI-guided focused ultrasound in rat glioma. Ultrasound Med. Biol.38(10), 1716–1725 (2012).
   PubMed Web of Science ®Google Scholar
• Ponce AM , VujaskovicZ, YuanFet al. Hyperthermia mediated liposomal drug delivery. Int. J. Hyperther.22(3), 205–213 (2006).
   PubMed Web of Science ®Google Scholar
• Song CW , ParkHJ, LeeCK, GriffinR. Implications of increased tumor blood flow and oxygenation caused by mild temperature hyperthermia in tumor treatment. Int. J. Hyperther.21(8), 761–767 (2005).
   PubMed Web of Science ®Google Scholar
• Landon CD , ParkJ-Y, NeedhamD, DewhirstMW. Nanoscale drug delivery and hyperthermia: the materials design and preclinical and clinical testing of low temperature-sensitive liposomes used in combination with mild hyperthermia in the treatment of local cancer. Open Nanomed. J.3(1), 38–64 (2011).
   PubMedGoogle Scholar
• Grüll H , LangereisS. Hyperthermia-triggered drug delivery from temperature-sensitive liposomes using MRI-guided high intensity focused ultrasound. J. Control. Rel.161(2), 317–327 (2012).
   PubMed Web of Science ®Google Scholar
• Mirza AN , FornageBD, SneigeNet al. Radiofrequency ablation of solid tumors. Cancer J.7(2), 95–102 (2001).
   PubMed Web of Science ®Google Scholar
• Ng KKC , PoonRTP, ChanSCet al. High-intensity focused ultrasound for hepatocellular carcinoma: a single-center experience. Ann. Surg.253(5), 981–987 (2011).
   PubMed Web of Science ®Google Scholar
• Fishman PS , FrenkelV. Focused ultrasound: an emerging therapeutic modality for neurologic disease. Neurotherapeutics14(2), 393–404 (2017).
   PubMed Web of Science ®Google Scholar
• Kok HP , CressmanENK, CeelenWet al. Heating technology for malignant tumors: a review. Int. J. Hyperther.37(1), 711–741 (2020).
   PubMed Web of Science ®Google Scholar
• Seynhaeve ALB , AminM, HaemmerichDet al. Hyperthermia and smart drug delivery systems for solid tumor therapy. Adv. Drug Deliv. Rev.163, 125–144 (2020).
   PubMed Web of Science ®Google Scholar
• Ngen EJ , AzadBB, BoinapallySet al. MRI assessment of prostate-specific membrane antigen (PSMA) targeting by a PSMA-targeted magnetic nanoparticle: potential for image-guided therapy. Mol. Pharm.16(5), 2060–2068 (2019).
   PubMedGoogle Scholar
• Li M , DengL, LiJet al. Actively targeted magnetothermally responsive nanocarriers/doxorubicin for thermochemotherapy of hepatoma. ACS Appl. Mater. Inter.10(48), 41107–41117 (2018).
   PubMed Web of Science ®Google Scholar
• Dilnawaz F , SinghA, MohantyC, SahooSK. Dual drug loaded superparamagnetic iron oxide nanoparticles for targeted cancer therapy. Biomaterials31(13), 3694–3706 (2010).
   PubMed Web of Science ®Google Scholar
• Wang Y , NgYW, ChenYet al. Formulation of superparamagnetic iron oxides by nanoparticles of biodegradable polymers for magnetic resonance imaging. Adv. Funct. Mater.18(2), 308–318 (2008).
   Web of Science ®Google Scholar
• Tak WY , LinS-M, WangYet al. Phase III HEAT study adding lyso-thermosensitive liposomal doxorubicin to radiofrequency ablation in patients with unresectable hepatocellular carcinoma lesions. Clin. Cancer Res.24(1), 73–83 (2018).
   PubMed Web of Science ®Google Scholar
• Kobayashi H , WatanabeR, ChoykePL. Improving conventional enhanced permeability and retention (EPR) effects; what is the appropriate target?Theranostics4(1), 81–89 (2013).
   PubMed Web of Science ®Google Scholar
• Kobayashi H , ChoykePL. Near-infrared photoimmunotherapy of cancer. Accounts Chem. Res.52(8), 2332–2339 (2019).
   PubMed Web of Science ®Google Scholar
• Kobayashi H , ChoykePL. Super enhanced permeability and retention (SUPR) effects in tumors following near infrared photoimmunotherapy. Nanoscale8(25), 12504–12509 (2015).
   PubMed Web of Science ®Google Scholar
• Pérez-Medina C , Abdel-AttiD, TangJet al. Nanoreporter PET predicts the efficacy of anti-cancer nanotherapy. Nat. Commun.7(1), 11838 (2016).
   PubMedGoogle Scholar
• Baghban R , RoshangarL, Jahanban-EsfahlanRet al. Tumor microenvironment complexity and therapeutic implications at a glance. Cell Commun. Signal.18(1), 59 (2020).
   PubMed Web of Science ®Google Scholar
• Belli C , TrapaniD, VialeGet al. Targeting the microenvironment in solid tumors. Cancer Treat. Rev.65, 22–32 (2018).
   PubMed Web of Science ®Google Scholar
• Fu Y , SaraswatAL, MonparaJ, PatelK. Stromal disruption facilitating invasion of a ‘nano-arsenal’ into the solid tumor. Drug Discov. Today27(4), 1132–1141 (2022).
   PubMed Web of Science ®Google Scholar
• Park J , ChoiY, ChangHet al. Alliance with EPR effect: combined strategies to improve the EPR effect in the tumor microenvironment. Theranostics9(26), 8073–8090 (2019).
   PubMed Web of Science ®Google Scholar
• Manzo A , MontaninoA, CarillioGet al. Angiogenesis inhibitors in NSCLC. Int. J. Mol. Sci.18(10), 2021 (2017).
   PubMed Web of Science ®Google Scholar
• Malakouti-Nejad M , BardaniaH, AliakbariFet al. Formulation of nanoliposome-encapsulated bevacizumab (Avastin): statistical optimization for enhanced drug encapsulation and properties evaluation. Int. J. Pharmaceut.590, 119895 (2020).
   PubMed Web of Science ®Google Scholar
• Gong L , GiacominiMM, GiacominiCet al. PharmGKB summary: sorafenib pathways. Pharmacogenet.Genom.27(6), 240–246 (2017).
   PubMed Web of Science ®Google Scholar
• Maj E , PapiernikD, WietrzykJ. Antiangiogenic cancer treatment: the great discovery and greater complexity (Review). Int. J. Oncol.49(5), 1773–1784 (2016).
   PubMed Web of Science ®Google Scholar
• Hu J , YuanX, WangFet al. The progress and perspective of strategies to improve tumor penetration of nanomedicines. Chinese Chem. Lett.32(4), 1341–1347 (2021).
   Web of Science ®Google Scholar
• Yang S , GaoH. Nanoparticles for modulating tumor microenvironment to improve drug delivery and tumor therapy. Pharm. Res.126, 97–108 (2017).
   Google Scholar
• Zhou Y , ChenX, CaoJ, GaoH. Overcoming the biological barriers in the tumor microenvironment for improving drug delivery and efficacy. J. Mater. Chem. B.8(31), 6765–6781 (2020).
   PubMed Web of Science ®Google Scholar
• Loeffler M , KrügerJA, NiethammerAG, ReisfeldRA. Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. J. Clin. Invest.119(2), 421 (2009).
   Web of Science ®Google Scholar
• Patel K , DoddapaneniR, SekarVet al. Combination approach of YSA peptide anchored docetaxel stealth liposomes with oral antifibrotic agent for the treatment of lung cancer. Mol. Pharmaceut.13(6), 2049–2058 (2016).
   PubMed Web of Science ®Google Scholar
• Chavanpatil MD , KhdairA, PanyamJ. Nanoparticles for cellular drug delivery: mechanisms and factors influencing delivery. J. Nanosci. Nanotechnol.6(9), 2651–2663 (2006).
   PubMed Web of Science ®Google Scholar
• Yu M , ZhengJ. Clearance pathways and tumor targeting of imaging nanoparticles. ACS Nano9(7), 6655–6674 (2015).
   PubMed Web of Science ®Google Scholar
• Wong P-P , DemirciogluF, GhazalyEet al. Dual-action combination therapy enhances angiogenesis while reducing tumor growth and spread. Cancer Cell.27(1), 123–137 (2015).
   PubMed Web of Science ®Google Scholar
• Tong RT , BoucherY, KozinSVet al. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res.64(11), 3731–3736 (2004).
   PubMed Web of Science ®Google Scholar
• Miller MA , ChandraR, CuccareseMFet al. Radiation therapy primes tumors for nanotherapeutic delivery via macrophage-mediated vascular bursts. Sci. Transl. Med.9(392), eaal0225 (2017).
   PubMed Web of Science ®Google Scholar
• Sindhwani S , ChanWCW. Nanotechnology for modern medicine: next step towards clinical translation. J. Intern. Med.290(3), 486–498 (2021).
   PubMed Web of Science ®Google Scholar
• Lancet JE , UyGL, CortesJEet al. Final results of a phase III randomized trial of CPX-351 versus 7+3 in older patients with newly diagnosed high risk (secondary) AML. J. Clin. Oncol.34(Suppl. 15), 7000 (2016).
   Web of Science ®Google Scholar
• Lencioni R , CioniD. RFA plus lyso-thermosensitive liposomal doxorubicin: in search of the optimal approach to cure intermediate-size hepatocellular carcinoma. Hepatic Oncol.3(3), 193–200 (2016).
   PubMed Web of Science ®Google Scholar
• Vaupel PW , KelleherDK. Pathophysiological and vascular characteristics of tumours and their importance for hyperthermia: heterogeneity is the key issue. Int. J. Hyperther.26(3), 211–223 (2010).
   PubMed Web of Science ®Google Scholar
• Manzoor AA , LindnerLH, LandonCDet al. Overcoming limitations in nanoparticle drug delivery: triggered, intravascular release to improve drug penetration into tumors. Cancer Res.72(21), 5566–5575 (2012).
   PubMed Web of Science ®Google Scholar
• Dou Y , HynynenK, AllenC. To heat or not to heat: challenges with clinical translation of thermosensitive liposomes. J. Control. Rel.249, 63–73 (2017).
   PubMed Web of Science ®Google Scholar
• Moghimi SM , PatelHM. Serum-mediated recognition of liposomes by phagocytic cells of the reticuloendothelial system – the concept of tissue specificity. Adv. Drug Deliv. Rev.32(1–2), 45–60 (1998).
   PubMed Web of Science ®Google Scholar
• Suk JS , XuQ, KimNet al. PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv. Drug Deliv. Rev.99(Pt A), 28–51 (2016).
   PubMed Web of Science ®Google Scholar
• Hussain Z , KhanS, ImranMet al. PEGylation: a promising strategy to overcome challenges to cancer-targeted nanomedicines: a review of challenges to clinical transition and promising resolution. Drug Deliv. Transl. Res.9(3), 721–734 (2019).
   PubMed Web of Science ®Google Scholar
• Wang S-H , LeeAC-L, ChenI-Jet al. Structure-based optimization of GRP78-binding peptides that enhances efficacy in cancer imaging and therapy. Biomaterials94, 31–44 (2016).
   PubMed Web of Science ®Google Scholar
• Saraswat A , VemanaHP, DukhandeVV, PatelK. Galactose-decorated liver tumor-specific nanoliposomes incorporating selective BRD4-targeted PROTAC for hepatocellular carcinoma therapy. Heliyon8(1), e08702 (2022).
   PubMed Web of Science ®Google Scholar
• Haute DV , BerlinJM. Challenges in realizing selectivity for nanoparticle biodistribution and clearance: lessons from gold nanoparticles. Ther. Deliv.8(9), 763–774 (2017).
   PubMed Web of Science ®Google Scholar
• Rosenblum D , JoshiN, TaoWet al. Progress and challenges towards targeted delivery of cancer therapeutics. Nat. Commun.9(1), 1410 (2018).
   PubMed Web of Science ®Google Scholar
• Wang Y , WangZ, XuCet al. A disassembling strategy overcomes the EPR effect and renal clearance dilemma of the multifunctional theranostic nanoparticles for cancer therapy. Biomaterials197, 284–293 (2019).
   PubMed Web of Science ®Google Scholar
• Wu J , ChenJ, FengYet al. An immune cocktail therapy to realize multiple boosting of the cancer-immunity cycle by combination of drug/gene delivery nanoparticles. Sci. Adv.6(40), eabc7828 (2020).
   PubMed Web of Science ®Google Scholar
• Mukosera GT , LiuT, ManaenMet al. Deferoxamine produces nitric oxide under ferricyanide oxidation, blood incubation, and UV-irradiation. Free Radical Bio. Med.160, 458–470 (2020).
   PubMed Web of Science ®Google Scholar
• Kim MJ , KimS-M, LeeEKet al. Tumor doubling time predicts response to sorafenib in radioactive iodine-refractory differentiated thyroid cancer. Endocr. J.66(7), 597–604 (2019).
   PubMed Web of Science ®Google Scholar
• Nakashima K , UematsuT, TakahashiKet al. Does breast cancer growth rate really depend on tumor subtype? Measurement of tumor doubling time using serial ultrasonography between diagnosis and surgery. Breast Cancer – Tokyo26(2), 206–214 (2019).
   PubMed Web of Science ®Google Scholar
• Hori K , ZhangQH, SaitoSet al. Microvascular mechanisms of change in tumor blood flow due to angiotensin II, epinephrine, and methoxamine: a functional morphometric study. Cancer Res.53(22), 5528–34 (1993).
   PubMed Web of Science ®Google Scholar
• Kalyane D , RavalN, MaheshwariRet al. Employment of enhanced permeability and retention effect (EPR): nanoparticle-based precision tools for targeting of therapeutic and diagnostic agent in cancer. Mater. Sci. Eng. C. Mater. Biol. Sci.98, 1252–1276 (2019).
   PubMed Web of Science ®Google Scholar
• Jäger D , JägerE, KnuthA. Immune responses to tumour antigens: implications for antigen specific immunotherapy of cancer. J. Clin. Pathol.54(9), 669–74 (2001).
   PubMed Web of Science ®Google Scholar
• Lurie DJ , MäderK. Monitoring drug delivery processes by EPR and related techniques – principles and applications. Adv. Drug Deliv. Rev.57(8), 1171–1190 (2005).
   PubMed Web of Science ®Google Scholar
• Walker S , BusattoS, PhamAet al. Extracellular vesicle-based drug delivery systems for cancer treatment. Theranostics9(26), 8001–8017 (2019).
   PubMed Web of Science ®Google Scholar
• Xulu KR , AugustineTN. Antiplatelet therapy combined with anastrozole induces features of partial EMT in breast cancer cells and fails to mitigate breast-cancer induced hypercoagulation. Int. J. Mol. Sci.22(8), 4153 (2021).
   PubMed Web of Science ®Google Scholar
• Xiao W , GaoH. The impact of protein corona on the behavior and targeting capability of nanoparticle-based delivery system. Int. J. Pharmaceut.552(1–2), 328–339 (2018).
   PubMed Web of Science ®Google Scholar
• Barrán-Berdón AL , PozziD, CaraccioloGet al. Time evolution of nanoparticle–protein corona in human plasma: relevance for targeted drug delivery. Langmuir29(21), 6485–6494 (2013).
   PubMed Web of Science ®Google Scholar
• Mahmoudi M , SheibaniS, MilaniASet al. Crucial role of the protein corona for the specific targeting of nanoparticles. Nanomedicine (Lond.)10(2), 215–226 (2015).
   PubMed Web of Science ®Google Scholar
• Corbo C , MolinaroR, ParodiAet al. The impact of nanoparticle protein corona on cytotoxicity, immunotoxicity and target drug delivery. Nanomedicine (Lond.)11(1), 81–100 (2016).
   PubMed Web of Science ®Google Scholar
• Yoo J-W , ChambersE, MitragotriS. Factors that control the circulation time of nanoparticles in blood: challenges, solutions and future prospects. Curr. Pharm. Design.16(21), 2298–307 (2010).
   PubMed Web of Science ®Google Scholar
• Barui AK , OhJY, JanaBet al. Cancer-targeted nanomedicine: overcoming the barrier of the protein corona. Adv. Ther.3(1), 1900124 (2020).
   Google Scholar
• Gawali P , JadhavBL. Synthesis of Ag/AgCl nanoparticles and their action on human serum albumin: a fluorescence study. Process Biochem.69, 106–122 (2018).
   Web of Science ®Google Scholar
• Patel A , SaraswatA, PatelH, ChenZ-S, PatelK. Palmitoyl carnitine-anchored nanoliposomes for neovasculature-specific delivery of gemcitabine elaidate to treat pancreatic cancer. Cancers.15(1), 182 (2022).
   PubMed Web of Science ®Google Scholar
• Maruyama K . Intracellular targeting delivery of liposomal drugs to solid tumors based on EPR effects. Adv. Drug Deliv. Rev.63(3), 161–169 (2011).
   PubMed Web of Science ®Google Scholar
• Armijo-Olivo S . The importance of determining the clinical significance of research results in physical therapy clinical research. Braz. J. Phys. Ther.22(3), 175–176 (2018).
   PubMed Web of Science ®Google Scholar
• Musselman KE . Clinical significance testing in rehabilitation research: what, why, and how?Phys. Ther. Rev.12(4), 287–296 (2007).
   Google Scholar
• Vartak R , SaraswatA, YangYet al. Susceptibility of lung carcinoma cells to nanostructured lipid carrier of ARV-825, a BRD4 degrading proteolysis targeting chimera. Pharm. Res.39(11), 2745–2759 (2022).
   PubMed Web of Science ®Google Scholar
• Voelkl B , VogtL, SenaES, WürbelH. Reproducibility of preclinical animal research improves with heterogeneity of study samples. PLOS Biol.16(2), e2003693 (2018).
   PubMed Web of Science ®Google Scholar
• Pusztai L , HatzisC, AndreF. Reproducibility of research and preclinical validation: problems and solutions. Nat. Rev. Clin. Oncol.10(12), 720–724 (2013).
   PubMed Web of Science ®Google Scholar
• Bae YH . Drug targeting and tumor heterogeneity. J. Control. Rel.133(1), 2–3 (2009).
   PubMed Web of Science ®Google Scholar
• Quencer KB , FriedmanT, ShethR, OkluR. Tumor thrombus: incidence, imaging, prognosis and treatment. Cardiovasc. Diagnosis Ther.7(3), S165–S177 (2017).
   PubMedGoogle Scholar
• Sun D , ZhouS, GaoW. What went wrong with anticancer nanomedicine design and how to make it right. ACS Nano14(10), 12281–12290 (2020).
   PubMed Web of Science ®Google Scholar
• Ngoune R , PetersA, von ElverfeldtDet al. Accumulating nanoparticles by EPR: a route of no return. J. Control. Rel.238, 58–70 (2016).
   PubMed Web of Science ®Google Scholar
• Rosenkrantz AB , FriedmanK, ChandaranaHet al. Current status of hybrid PET/MRI in oncologic imaging. Am. J. Roentgenol.206(1), 162–172 (2016).
   PubMed Web of Science ®Google Scholar
• Herzog E , TaruttisA, BeziereNet al. Optical imaging of cancer heterogeneity with multispectral optoacoustic tomography. Radiology263(2), 461–468 (2012).
   PubMed Web of Science ®Google Scholar
• Dorbala S , AnanthasubramaniamK, ArmstrongISet al. Single photon emission computed tomography (SPECT) myocardial perfusion imaging guidelines: instrumentation, acquisition, processing, and interpretation. J. Nucl. Cardiol.25(5), 1784–1846 (2018).
   PubMed Web of Science ®Google Scholar
• Podoloff DA , AdvaniRH, AllredCet al. NCCN task force report: positron emission tomography (PET)/computed tomography (CT) scanning in cancer. J. Natl. Compr. Cancer Netw.5(Suppl. 1), S1-22, S23-2 (2007).
   PubMedGoogle Scholar
• Hafeez MN , CeliaC, PetrikaiteV. Challenges towards targeted drug delivery in cancer nanomedicines. Process9(9), 1527 (2021).
   Web of Science ®Google Scholar
• Matsumura Y . Principle of CAST strategy. In: Cancer Drug Delivery Systems Based on the Tumor Microenvironment.Springer, Tokyo, Japan, 255–267 (2019).
   Google Scholar
• Shi Y , vander Meel R, ChenX, LammersT. The EPR effect and beyond: strategies to improve tumor targeting and cancer nanomedicine treatment efficacy. Theranostics10(17), 7921–7924 (2020).
   PubMed Web of Science ®Google Scholar
• Bor G , AzmiIDM, YaghmurA. Nanomedicines for cancer therapy: current status, challenges and future prospects. Ther. Deliv.10(2), 113–132 (2019).
   PubMed Web of Science ®Google Scholar
• Wilson B , KMG. Artificial intelligence and related technologies enabled nanomedicine for advanced cancer treatment. Nanomedicine (Lond.)15(05), 433–435 (2020).
   PubMedGoogle Scholar
• Khade BS , WaghmareMN, BhatawaleNet al. A quantitative fluorescence study of α-amylase with different sizes of colloidal silver nanoparticles and its effect on human lung carcinoma A549 cells. Adv. Sci. Eng. Med.12(5), 662–671 (2020).
   Google Scholar
• Acebes-Fernández V , Landeira-ViñuelaA, Juanes-VelascoPet al. Nanomedicine and onco-immunotherapy: from the bench to bedside to biomarkers. Nanomaterials (Basel)10(7), 1274 (2020).
   PubMedGoogle Scholar
• Xu X , HoW, ZhangXet al. Cancer nanomedicine: from targeted delivery to combination therapy. Trends Mol. Med.21(4), 223–232 (2015).
   PubMed Web of Science ®Google Scholar